Key points are not available for this paper at this time.
Abstract Among various genetic mutation in melanoma, BRAFV600E is one of the key drivers of melanoma initiation and progression and has become the frontline target in clinical trials. Although BRAF/MEK inhibitors show very promising therapeutic outcomes, recurrence or relapse is still a major challenge and its underlying mechanisms are still poorly understood. We hypothesized that survival of recurrent tumors is BRAF independent and relies on epigenetic reprogramming. To test our hypothesis, we used either pharmacological inhibition of BRAF/MEK or CRISPR/Cas9 mediated knockout of BRAF to create cell/tumor models of BRAF-independent survival. Cut Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 4399.
Mou et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: